Objective: Receptor for advanced glycation end products (RAGE), along with its ligand high mobility group box 1 (HMGB1), is believed to play an important role in prostate cancer. The aim of this retrospective study was to investigate the expression of RAGE and HMGB1 and their clinical impact on prostate cancer progression and prognosis. Methods: The expression of RAGE and HMGB1 were assessed by immunohistochemistry in cancer lesions from 85 confirmed prostate cancer cases. We determined the potential association between the expression level of these two proteins and the clinicopathological features and overall patient survival. Results: The RAGE and HMGB1 were expressed in 78.8% (67/85) and 68.2% (58/85) cases of prostate cancers, respectively, and in the majority (54/85) of cases, these two proteins were co-expressed. There was a strong correlation between RAGE and HMGB1 expressions (P<0.001). The expression of RAGE, HMGB1 and their co-expression were all associated with advanced tumor clinical stage (P<0.05 for all). RAGE expression was also associated with the prostate specific antigen (PSA) level (P=0.014). However, neither the individual expression of those genes nor their co-expression was significantly related with age and Gleason score. The co-expression of RAGE and HMGB1 was associated with poor overall survival in patients with stage III and IV prostate cancer (P=0.047). Conclusions: These results suggest that the expression of RAGE and HMGB1 is associated with the progression and poor prognosis of prostate cancer. RAGE and HMGB1 could be new prognostic biomarkers for prostate cancer as well as molecular target for novel forms of therapies. 
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Objective: To test the expression of serine/arginine rich splicing factor 1 (SRSF1) and survivin [poptosis inhibiting factor (survivin)] in prostate cancer organizations, and study their correlation with the pathological features of prostate cancer, thus put forward the new targets in the treatment of prostate cancer. Methods: SRSF1, survivin protein was analyzed in 20 prostate tissue samples including prostate cancer and benign prostatic hyperplasia by immunohistochemical SP method. SRSF1, survivin was correlated to pathological features, and both the relevance was analyzed (no related reports at home and abroad).
Results:
The positive expression rate of SRSF1 protein in prostate cancer tissue cells was 76.37%±5.06%, significantly higher than that of benign prostatic hyperplasia 11.30%+1.09% (P<0.05); the positive expression rate of survivin protein in prostate cancer tissue cells was 86.93%±3.21%, significantly higher than that of benign prostatic hyperplasia 17.67%±1.99% (P<0.05); SRSF1 and survivin protein expressed in prostate cancer organizations and were positively correlated to pathological Gleason grading, and the second Have significant correlation (P<0.05). Conclusions: SRSF1 and survivin protein were highly expressed in adenocarcinoma tissue, significantly increased than that of benign hyperplasia of prostate tissue. The positive expression SRSF1 and survivin protein were positively correlated to pathological Gleason grading. The expression of survivin protein was elevated with the expression of survivin SRSF1protein in prostate cancer. Preliminary evidence about the role of SRSF1 may be through up-regulation the expression of survivin, thus promote the occurrence and development of prostate cancer. Objective: Numerous studies have shown associations between the FOX03A gene, encoding the forkhead box 03 transcription factor, and human or specifically male longevity. However, the associations of specific FOX03A polymorphisms with longevity remain inconclusive. We performed a meta-analysis of existing studies to clarify these potential associations. Methods: A comprehensive search was conducted to identify studies of FOX03A gene polymorphisms and longevity. Pooled odds ratios (ORs) and 95% confidence intervals (Cls) were calculated by comparing the minor and major alleles. Results: A total of seven articles reporting associations of FOX03A polymorphisms with longevity were identified and included in this meta-analysis. These comprised 11 independent studies with 5241 cases and 5724 controls from different ethnic groups. rs2802292, rs2764264, rsI3217795, rs1935949 and rs2802288 polymorphisms were associated with human longevity (OR =1.36, 95% CI, 1. 10-1.69, P=0.005; OR =1.20, 95% CI, 1.04-1.37, P=0.01; OR =1.27, 95% CI, 1.10-1.46, P=0.001; OR =1.14, 95% CI, 1.01-1.27 and OR =1.24, 95% CI, 1.07-1.43, P=0.003, respectively). Analysis is stratified by gender indicated significant associations between rs2802292, rs2764264 and rs13217795 and male longevity (OR =1.54, 95% CI, 1.33-1.79, P<0.001; OR =1.38, 95% CI, 1.15-1.66, P=0.001; and OR =1.39, 95% CI, 1.15-1.67, P=0.001), but rs2802292, rs2764264 and rs1935949 were not linked to female longevity. Moreover, our study showed no association between rs2153960, rs7762395 or rs13220810 polymorphisms and longevity. Conclusions: In conclusion, this meta-analysis indicates a significant association of five FOX03A gene polymorphisms with longevity, with the effects of rs2802292 and rs2764264 being male-specific. Further investigations are required to confirm these findings. Objective: To develop Tet-regulated small hairpin RNA (shRNA) that inhibits the malignant phenotypes of tumor cell through Ribonucleic acid interference (RNAi). Methods: Here we build a type of tetracycline (Tet)-inducible vectors which can achieve regulatable expression of shRNA in a time-dependent manner by using synthetic biology approach. In order to prove the effectiveness of this device, we chose hTERT and Bcl-2 as target genes and test the utility of the device on 5637 and T24 cell lines.
The experiments show that the Tet-inducible small hairpin RNA can effectively suppress their target genes
